Bio­Marin broad­ens its gene ther­a­py hori­zons with a new R&D al­liance in rare car­dio cas­es

Bio­Marin has just struck a deal to back a Swiss biotech start­up with some deep ties to top re­search in­sti­tu­tion UCL in Lon­don as it beefs up the swelling gene ther­a­py por­tion of the pipeline.

We don’t have any terms to deal with, just the knowl­edge that Bio­Marin CEO JJ Bi­en­aimé saw enough of Di­NAQOR’s work to in­vest in the com­pa­ny as it li­cens­es their lead pre­clin­i­cal pro­gram, Di­NA-001 for MYBPC3 hy­per­trophic car­diomy­opa­thy, while col­lab­o­rat­ing on the rest of the pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER